Evotec

Evotec is a German‑based contract research organisation that specialises in the discovery and development of small‑molecule and biologic therapeutics for pharmaceutical and biotechnology partners. Its service portfolio spans target identification, hit generation, lead optimisation, preclinical development, and early‑stage clinical support, delivered through integrated chemistry, biology, and DMPK platforms. The company serves a global clientele that includes large multinational pharma firms, mid‑size biotech enterprises, and academic research groups seeking outsourced expertise to accelerate their drug pipelines. By offering end‑to‑end capabilities under a single contractual framework, Evotec enables partners to reduce internal overhead and focus resources on later‑stage development stages.

The firm distinguishes itself through a highly integrated discovery platform that combines medicinal chemistry, assay development, structural biology, and computational modelling to drive rapid iteration.centrecentredesign and to meet meet the need for potency, selectivity, and drug‑likeness optimisation early in the project lifecycle. Evotec places a strong emphasis on scientific innovation, maintaining a robust pipeline of proprietary technologies such as its INDUCE™ target‑validation system and its EVEX™ protein‑production platform, which are frequently highlighted in scientific collaborations and publications. Its regulatory expertise supports partners in navigating IND‑enabling studies and complying with GLP and GMP standards where required, positioning the organisation as a trusted advisor in early‑stage drug development. The company’s culture of scientific excellence is reflected in its numerous award‑winning projects and long‑term partnerships with leading healthcare organisations.

Evotec operates as an independent, publicly listed entity under the legal form of an Aktiengesellschaft (AG) and is traded on the Frankfurt Stock Exchange under the ticker symbol EVT. The company’s ownership structure comprises a diverse base of institutional and retail investors, with no single majority shareholder reported in its public filings. While it maintains wholly owned subsidiaries in various countries to support its global delivery model, the parent Evotec AG retains strategic control over corporate governance, financial reporting, and overall corporate direction. This organisational setup allows Evotec to balance local operational flexibility with centralized oversight of quality, compliance, and innovation initiatives across its international sites.